ArticleBMC infectious diseases2026
Maternal and infant predictors of early mother-to-child transmission among HIV-exposed infants in the Karamoja region, Northeastern Uganda 2020-2023, a retrospective cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite Uganda making significant progress in reducing mother-to-child transmission (eMTCT), from 20% in 2000 to 2.8% in 2021, regional differences in MTCT rates exist. The drivers of these differences remain unclear in some nomadic populations of the Karamoja region. This study aimed to determine the maternal and infant predictors of HIV infection among HIV-exposed infants (HEI) under 18 months of age in the Karamoja region, Northeastern Uganda.
methodsWe conducted a retrospective cross-sectional study across twelve public health facilities in Karamoja, Uganda. Data on mothers and their HEI who had their first HIV nucleic acid amplification test at 4 to 6 weeks of age by either dry blood test or point of care testing were abstracted from the Early Infant Diagnosis (EID) register. The primary outcome was an HEI PCR test result (Positive or Negative). Firth’s penalized likelihood regression was used to determine factors associated with Infant HIV positivity. Data was analyzed using STATA version 15, and a p-value of < 0.05 was considered significant.
resultsA total of 223 mother-baby pairs were included in the analysis, with 52.9% (n=118) of the HEI being female, and the maternal median age was 27 (interquartile range 23-30). The Infant HIV positivity was 2.2% (n=5) and was significantly lower among mothers with no advanced HIV disease (stage 1 or 2)[adjusted odds ratio (aOR): 0.008, 95% confidence interval (CI): 0.0002- 0.35 P=0.012], Mothers having a suppressed viral load (<1000 copies/ml) [aOR: 0.019, 95% CI: 0.0011- 0.36, P=0.008] and infants who received Nevirapine [aOR: 0.038, 95% CI: 0.0015 - 0.922, P=0.044].
conclusionThe results showed that maternal viral suppression, absence of advanced HIV disease, and infant receipt of nevirapine prophylaxis were associated with lower infant HIV positivity. Ensuring mother-baby pairs receive all the eMTCT services can avert new HIV infections among the HEI. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.